The Pancreatic Cancer Action Network has announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The organization also announces the 12 initial Precision Promise Clinical Trial Consortium sites selected to participate in this groundbreaking initiative.
Bringing together the field’s key stakeholders, including clinicians, researchers and diagnostic and drug developers, Precision Promise will put the patient at the center of every decision and will advance the Pancreatic Cancer Action Network’s goal to double survival by 2020. The Pancreatic Cancer Action Network has committed a minimum initial investment of $35 million over the first four years, not including drug costs, and expects to enroll thousands of patients.
“Precision Promise will dramatically accelerate the clinical trial process to bring promising therapies to patients faster,” said Julie Fleshman, JD, MBA, president and CEO of the Pancreatic Cancer Action Network. “Precision Promise is an unprecedented opportunity for patients and is vital to move the field forward. Instead of looking for the right patient for a clinical trial, we are designing the right clinical trial for each patient.”